The Trump administration is weighing “severe restrictions” on the growing flow of drugs from China, the New York Times reported Wednesday. A draft executive order being circulated to pharmaceutical firms and investors accuses China "and other hostile actors” of exploiting gaps in U.S. scientific and regulatory systems. Proposals include requiring the FDA to subject Chinese clinical trial data to stricter reviews and higher fees, while also boosting domestic production of medicines like antibiotics and acetaminophen, with U.S.-made products given government purchasing preference. The newspaper also noted discussions about speeding up FDA reviews to let drugmakers launch studies faster, echoing China’s own regulatory reforms. China has emerged as a key source of biotech innovation, accounting for 32% of global outlicensing deal value in early 2025, up from 21% in the prior two years.